Trial Profile
Open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma who have received radical surgery. A European Association of Urology Research Foundation Phase II Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Pemigatinib (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms PEGASUS
- 13 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 25 Jan 2022 Planned End Date changed from 30 Oct 2024 to 24 Sep 2023.
- 25 Jan 2022 Planned primary completion date changed from 30 Apr 2024 to 24 Sep 2023.